Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9692838 | 0.86 | SIGMAR1 (0.50) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL8578247 | 0.82 | SIGMAR1 (0.42) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL6677531 | 0.82 | SIGMAR1 (0.42) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL12056268 | 0.82 | CA2 (0.49) | HTR1ANISCHDRD1 | |
| SCHEMBL13572973 | 0.81 | SIGMAR1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL13572976 | 0.81 | SIGMAR1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL8354157 | 0.81 | SIGMAR1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL20864244 | 0.81 | SIGMAR1 (0.56) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL8578251 | 0.81 | SIGMAR1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 | |
| SCHEMBL716596 | 0.81 | SIGMAR1 (0.52) | SIGMAR1HTR1AOPRM1OPRL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117069720-A | 5-HT 2A Receptor agonist, preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2020-07-23 | — | — | US | disclosed |
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3599236-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2020-01-29 | — | — | EP | disclosed |
| EP-3202460-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| EP-1480983-A1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYDIMIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | Sanofi-Aventis (FR) | 2004-12-01 | — | — | EP | disclosed |
| EP-1480641-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | CHENG XUE-MIN (US) | 2003-11-06 | — | — | US | disclosed |
| EP-1348708-A1 | Heteroaryl substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003074051-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (GB) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003072579-A1 | HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9- TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2003-09-04 | — | — | WO | disclosed |
| US-5112855-A | Nootropic Agents | CIBA-GEIGY CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0252005-B1 | HYDROGENATED 1-BENZOOXACYCLOALKYL-PYRIDINE CARBOXYLIC-ACID COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-07-10 | — | — | EP | disclosed |
| US-4957928-A | NOOTROPIC AGENTS, COGNITION ACTIVATORS | CIBA-GEIGY CORPORATION (US) | 1990-09-18 | — | — | US | disclosed |
| EP-0252005-A1 | Hydrogenated 1-benzooxacycloalkyl-pyridine carboxylic-acid compounds | CIBA-GEIGY AG (CH) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669257-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | SIGMAR1 264/4885HTR1A 189/4885OPRM1 123/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | SIGMAR1 264/4885HTR1A 189/4885OPRM1 123/4885 |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | SIGMAR1 264/4885HTR1A 189/4885OPRM1 123/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | SIGMAR1 264/4885HTR1A 189/4885OPRM1 123/4885 |
| US-20190135780-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | SIGMAR1 264/4885HTR1A 189/4885OPRM1 123/4885 |
| US-20030207915-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARD, PPARG | SIGMAR1 3188/4885HTR1A 1664/4885OPRM1 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.